| abstract |
The present invention relates to methods, compositions and kits related to resistance to treatment with anticancer agents, in particular BRAF inhibitors. In particular embodiments, the invention relates to mutations in BRAF sequences that confer resistance to BRAF inhibitors. Identification of these mutations in the BRAF sequence allows the identification and design of next generation BRAF inhibitors. Methods and kits are also provided for detecting the presence of a mutant BRAF sequence in a sample. |